Next Century Growth Investors LLC Has $2.80 Million Holdings in SiBone $SIBN

Next Century Growth Investors LLC grew its stake in shares of SiBone (NASDAQ:SIBN) by 508.4% in the 4th quarter, HoldingsChannel reports. The fund owned 141,998 shares of the company’s stock after purchasing an additional 118,657 shares during the quarter. Next Century Growth Investors LLC’s holdings in SiBone were worth $2,800,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of SIBN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in SiBone by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock worth $343,000 after acquiring an additional 1,053 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in SiBone during the first quarter worth approximately $225,000. Goldman Sachs Group Inc. lifted its position in SiBone by 28.4% during the first quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company’s stock worth $5,328,000 after acquiring an additional 83,919 shares during the last quarter. Jane Street Group LLC acquired a new stake in SiBone during the first quarter worth approximately $1,818,000. Finally, Legal & General Group Plc lifted its position in SiBone by 16.1% during the second quarter. Legal & General Group Plc now owns 42,403 shares of the company’s stock worth $798,000 after acquiring an additional 5,888 shares during the last quarter. 98.11% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at SiBone

In other SiBone news, Director Jeffrey W. Dunn sold 3,575 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $15.25, for a total transaction of $54,518.75. Following the completion of the transaction, the director directly owned 16,057 shares in the company, valued at $244,869.25. The trade was a 18.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Anshul Maheshwari sold 3,318 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $12.87, for a total transaction of $42,702.66. Following the transaction, the chief financial officer owned 263,148 shares of the company’s stock, valued at approximately $3,386,714.76. This represents a 1.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 36,327 shares of company stock valued at $520,834. 3.90% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have issued reports on SIBN. Truist Financial restated a “buy” rating and set a $18.00 price objective (down from $20.00) on shares of SiBone in a research report on Tuesday, May 12th. Wall Street Zen downgraded shares of SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Finally, TD Cowen lowered their target price on shares of SiBone from $22.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, SiBone currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

SiBone Stock Performance

Shares of SIBN stock opened at $15.42 on Monday. The company has a current ratio of 9.99, a quick ratio of 8.34 and a debt-to-equity ratio of 0.20. The stock has a market cap of $683.88 million, a P/E ratio of -39.54 and a beta of 0.70. The stock has a 50 day simple moving average of $13.94 and a 200 day simple moving average of $15.81. SiBone has a 1 year low of $11.48 and a 1 year high of $21.89.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.07. The business had revenue of $52.59 million during the quarter, compared to analysts’ expectations of $51.16 million. SiBone had a negative return on equity of 9.56% and a negative net margin of 8.10%. On average, research analysts predict that SiBone will post -0.44 earnings per share for the current fiscal year.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.